alemtuzumab (campath) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$8392.0798

United States

$16714.3200 - $21094.6300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

alemtuzumab | campath | campath 1g | campath-1g | campath-1-g | campath 1h | campath-1h | campath 1m | campath-1m | campath mabcampath, lemtrada | humanized anti-cd52 | ldp-03 | lemtrada | mabcambath | mabcampath | monoclonal antibody campath-1h

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue